Abstract:OPCML, a GPI anchored tumor suppressor gene is inactivated by somatic methylation in multiple cancers. We previously identified this gene by LOH mapping and demonstrated that it was inactivated by somatic methylation in 80% of ovarian cancers. Restoring OPCML expression by stable transfection suppressed in-vitro growth and in-vivo tumorigenicity. We hypothesized that OPCML might abrogate growth signaling pathways. In SKOV-3 and PEO1, ovarian cancer cell lines with no expression of OPCML, we demonstrated that OPCML negatively regulates a specific repertoire of receptor tyrosine kinases (RTKs) EPHA2, FGFR1, FGFR3, HER2 and HER4, and reciprocally, OPCML siRNA knockdown in normal ovarian surface epithelial cells up-regulates these same RTKs, with no effect on RTKs EPHA10, FGFR2, FGFR4, EGFR, HER3, VEGFR1 and VEGFR3. Example immunoprecipitation experiments revealed that OPCML binds to EphA2, FGFR1 and HER2 extracellular domains with no such interaction to EGFR, thus OPCML binds directly to RTKS that it negatively regulates. We demonstrate that OPCML is located exclusively in the raft membrane fraction and sequesters RTKs that it binds to the raft fraction, leading to polyubiquitination and proteosomal degradation via a cav-1 endosomal mechanism resulting in systems depletion of this specific RTK repertoire, that does not occur with RTKs that OPCML does not bind. We demonstrate that OPCML abrogates EGF mediated phosphorylation of FGFR1, HER2 and EGFR and the downstream phosphosignaling of pErk and pAKT. A recombinant modified OPCML-like protein without a GPI anchor, signal peptide or glycosylation was constructed and expressed in E.Coli. This rOPCML tumor suppressor protein therapeutic caused growth inhibition by apoptosis in 6/7 ovarian cancer cell lines tested with no effect on OPCML expressing normal ovarian surface epithelium by an identical mechanism to the transfected normal protein. rOPCML was then injected intraperitoneally twice weekly in two murine intraperitoneal models of ovarian cancer (nude mouse A2780 and SKOV3) and demonstrated profound inhibition of tumour weight, ascites volume and peritoneal dissemination compared with BSA control. In Summary, the OPCML tumour suppressor mediates its suppressor function by systems level negative regulation of at least 5 RTKs and a recombinant modified derivative is a potent tumor suppressor protein therapeutic in-vitro and in-vivo. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1616. doi:10.1158/1538-7445.AM2011-1616

Opcml Is A Broad Tumor Suppressor For Multiple Carcinomas And Lymphomas With Frequently Epigenetic Inactivation

Pharmacologic demethylation identifies UCHL1 as a tumor suppressor gene frequently silenced in nasopharyngeal and multiple other carcinomas

OPCML is Frequently Methylated in Human Colorectal Cancer and Its Restored Expression Reverses EMT Via Downregulation of Smad Signaling.

Association of Abnormal Methylation of CpG Islands in Promoter Domains of Multiple Tumor Suppressor Genes with Non-Small Cell Lung Cancer

Deletion of OPCML Gene and Promoter Methylation in Ovarian Epithelial Carcinoma

OPCML Gene Promoter Methylation and Gene Expression in Tumor and Stroma Cells of Invasive Cervical Carcinoma

Loss of OPCML Expression and the Correlation with CpG Island Methylation and LOH in Ovarian Serous Carcinoma.

Expression and Promoter Methylation Status of OPCML and Its Functions in the Inhibition of Cell Proliferation, Migration, and Invasion in Breast Cancer

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

The Opcml Tumor Suppressor Negatively Regulates A Specific Repertoire Of 5 Receptor Tyrosine Kinases Via A Novel Proteasomal Mechanism, And Its Recombinant Derivative Is A Potent In-Vivo Anticancer Protein Therapy

Epigenetic identification of CHD5 as a critical 1p36.3 tumor suppressor frequently inactivated by promoter methylation in multiple carcinomas

Epigenetic Disruption of Interferon-Γ Response Through Silencing the Tumor Suppressor Interferon Regulatory Factor 8 in Nasopharyngeal, Esophageal and Multiple Other Carcinomas

Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer

The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas

Data from <i>CMTM3</i>, Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis

Supplementary Figure 7 from the OPCML Tumor Suppressor Functions As a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer

Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma.

Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas

Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes.

Cmtm3, Located At The Critical Tumor Suppressor Locus 16q22.1, Is Silenced By Cpg Methylation In Carcinomas And Inhibits Tumor Cell Growth Through Inducing Apoptosis

Epigenetic Identification of Receptor Tyrosine Kinase-Like Orphan Receptor 2 As a Functional Tumor Suppressor Inhibiting Β-Catenin and AKT Signaling but Frequently Methylated in Common Carcinomas.